Correlation between adherence to antiepileptic drugs and quality of life in patients with epilepsy: A longitudinal study

Lin, CY; Chen, H; Pakpour, AH

Correlation between adherence to antiepileptic drugs and quality of life in patients with epilepsy: A longitudinal study

Lin, CY Chen, H

Pakpour, AH

Permalink

Publication Type:: Journal Article
Citation:: Epilepsy and Behavior, 2016, 63 pp. 103 - 108
Issue Date:: 2016-10-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Microsoft Word

Download Accepted Manuscript VersionMicrosoft Word (164 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Lin, CY	en_US
dc.contributor.author	Chen, H https://orcid.org/0000-0001-6883-3752	en_US
dc.contributor.author	Pakpour, AH	en_US
dc.date.available	2020-05-25T19:13:45Z
dc.date.issued	2016-10-01	en_US
dc.identifier.citation	Epilepsy and Behavior, 2016, 63 pp. 103 - 108	en_US
dc.identifier.issn	1525-5050	en_US
dc.identifier.uri	http://hdl.handle.net/10453/51904
dc.description.abstract	© 2016 Elsevier Inc. Objective This study aimed to investigate whether the score of self-reported medication adherence using the Medication Adherence Report Scale (MARS-5) correlates with the serum level of antiepileptic medication, as well as whether the MARS-5 score can predict the quality of life (QoL) in patients with epilepsy. Methods A longitudinal study was carried out. The patients with epilepsy who were prescribed a minimum of one antiepileptic drug were recruited (n = 807). Each participant completed a background information sheet and the MARS-5 at baseline, followed by the Liverpool Seizure Severity Scale (LSSS) and Quality of Life in Epilepsy (QOLIE-31) questionnaire at 18-month follow-up. In addition, the serum level of antiepileptic medications was measured at the follow-up. Results The MARS-5 score was negatively associated with the LSSS score (B = − 0.089, SE = 0.009, p < 0.001) and positively correlated with the serum level of antiepileptic medications (B = 3.200, SE = 0.416, p < 0.001), after adjusting for demographics and clinical characteristics. The serum level of antiepileptic drugs was significantly correlated with the overall QOLIE-31 score (B = 3.118, SE = 1.417, p = 0.03). The MARS-5 score was significantly correlated with the overall QOLIE-31 scores and all the scores in the subcategories. In addition, the MARS-5 score was in line with the correlation between the LSSS and QOLIE-31 scores (Z = 4.20, p < 0.001) and between serum antiepileptic medication levels and QOLIE-31 score (Z = 3.98, p < 0.001). Conclusions The MARS-5 score can predict the QoL in patients with epilepsy for up to 18 months. Therefore, healthcare providers may predict the QoL and drug adherence using the MARS-5 score, in order to design personalized interventions.	en_US
dc.relation.ispartof	Epilepsy and Behavior	en_US
dc.relation.isbasedon	10.1016/j.yebeh.2016.07.042	en_US
dc.subject.classification	Neurology & Neurosurgery	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Epilepsy	en_US
dc.subject.mesh	Anticonvulsants	en_US
dc.subject.mesh	Longitudinal Studies	en_US
dc.subject.mesh	Quality of Life	en_US
dc.subject.mesh	Adult	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Male	en_US
dc.subject.mesh	Medication Adherence	en_US
dc.subject.mesh	Surveys and Questionnaires	en_US
dc.title	Correlation between adherence to antiepileptic drugs and quality of life in patients with epilepsy: A longitudinal study	en_US
dc.type	Journal Article
utslib.citation.volume	63	en_US
utslib.for	1103 Clinical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	open_access
pubs.publication-status	Published	en_US
pubs.volume	63	en_US

Abstract:

© 2016 Elsevier Inc. Objective This study aimed to investigate whether the score of self-reported medication adherence using the Medication Adherence Report Scale (MARS-5) correlates with the serum level of antiepileptic medication, as well as whether the MARS-5 score can predict the quality of life (QoL) in patients with epilepsy. Methods A longitudinal study was carried out. The patients with epilepsy who were prescribed a minimum of one antiepileptic drug were recruited (n = 807). Each participant completed a background information sheet and the MARS-5 at baseline, followed by the Liverpool Seizure Severity Scale (LSSS) and Quality of Life in Epilepsy (QOLIE-31) questionnaire at 18-month follow-up. In addition, the serum level of antiepileptic medications was measured at the follow-up. Results The MARS-5 score was negatively associated with the LSSS score (B = − 0.089, SE = 0.009, p < 0.001) and positively correlated with the serum level of antiepileptic medications (B = 3.200, SE = 0.416, p < 0.001), after adjusting for demographics and clinical characteristics. The serum level of antiepileptic drugs was significantly correlated with the overall QOLIE-31 score (B = 3.118, SE = 1.417, p = 0.03). The MARS-5 score was significantly correlated with the overall QOLIE-31 scores and all the scores in the subcategories. In addition, the MARS-5 score was in line with the correlation between the LSSS and QOLIE-31 scores (Z = 4.20, p < 0.001) and between serum antiepileptic medication levels and QOLIE-31 score (Z = 3.98, p < 0.001). Conclusions The MARS-5 score can predict the QoL in patients with epilepsy for up to 18 months. Therefore, healthcare providers may predict the QoL and drug adherence using the MARS-5 score, in order to design personalized interventions.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/51904